首页 | 本学科首页   官方微博 | 高级检索  
     


Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension
Authors:Ziesche R  Petkov V  Wittmann K  Kopatschka J  Stiebellehner L  Schenk P  Germann P  Röder G  Ullrich R  Block L H
Affiliation:Department of Internal Medicine IV, University of Vienna Medical School, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
Abstract:OBJECTIVE—To assess whether long term treatment with epoprostenol might restore primary non-responsiveness to nitric oxide (NO) in patients with primary pulmonary hypertension.
METHODS—Seven patients with primary pulmonary hypertension receiving intravenous epoprostenol continuously because of failure of NO to influence pulmonary haemodynamics during initial testing were followed over a period of 13-29 months. Afterwards, acute vascular reactivity towards NO was tested again during right heart catheterisation.
RESULTS—Administration of NO after continuous epoprostenol treatment for a mean period of 18 months improved arterial oxygen saturation (p < 0.01) and cardiac index (p < 0.05), and decreased mean pulmonary artery pressure (p < 0.01) and total pulmonary vascular resistance (p < 0.01) in patients previously unresponsive to NO.
CONCLUSIONS—Long term treatment with epoprostenol reverts initial refractoriness to NO in patients with primary pulmonary hypertension. Thus the addition of NO to epoprostenol treatment might cause further improvement in the course of the disease.


Keywords: primary pulmonary hypertension; epoprostenol; vascular reactivity
Keywords:primary pulmonary hypertension   epoprostenol   vascular reactivity
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号